The Long Immortal Time Bias in the Study

Patrick O'Neill: The dropout rate brings up a lot of questions. Are these heavily, heavily enriched patients to do very well? And then also your question of immortal time bias?" He says the survival curve "looks absolutely incredible," but if you're enriching it for really good patients, then blend a tumor MAB has even less of a chance to improve outcomes. 'We love speculating about every single study here,' he adds; 'that's what we do.'